Yarrow Bioscience (NASDAQ:YARW) & Zenas BioPharma (NASDAQ:ZBIO) Head to Head Analysis

Yarrow Bioscience (NASDAQ:YARW) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Institutional & Insider Ownership

83.8% of Yarrow Bioscience shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Yarrow Bioscience has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500.

Profitability

This table compares Yarrow Bioscience and Zenas BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Zenas BioPharma	N/A	-122.45%	-58.04%

Analyst Recommendations

This is a summary of current ratings and price targets for Yarrow Bioscience and Zenas BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1	0	3	0	2.50
Zenas BioPharma	1	2	6	0	2.56

Yarrow Bioscience presently has a consensus price target of $59.00, indicating a potential upside of 273.65%. Zenas BioPharma has a consensus price target of $46.71, indicating a potential upside of 63.51%. Given Yarrow Bioscience’s higher possible upside, research analysts clearly believe Yarrow Bioscience is more favorable than Zenas BioPharma.

Earnings and Valuation

This table compares Yarrow Bioscience and Zenas BioPharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570,000.00	73.96	-$26.48 million	($14.64)	-1.08
Zenas BioPharma	$10.00 million	186.22	-$377.74 million	($9.42)	-3.03

Yarrow Bioscience has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Zenas BioPharma beats Yarrow Bioscience on 8 of the 13 factors compared between the two stocks.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.